Meier-Gorlin Syndrome (MGS), a form of human proportionate dwarfism, arises from mutations in proteins needed for chromosome replication, including the origin recognition complex protein Orc4. Yeast cells (S. cerevisiae) with the mutant allele (orc4MGS) have altered origin activity across the genome, but most dramatically, origin activity in the rDNA is abolished. The orc4MGS cells also display secondary phenotypes such as slow growth, temperature sensitivity, and sensitivity to the drugs hydroxyurea and cycloheximide. To deal with the lack of rDNA origin activity yeast with fewer rDNA repeats (about 10) overtake the culture. My research focuses on understanding whether the secondary yeast phenotypes are due to fewer rDNA repeats, or other consequences of mutant Orc4. To explore the distinction, I am using CRISPR/-Cas9, a system for precise gene editing, to replace the origins of replication in the rDNA region with more efficient origins (ARS1 and ARS1max). CHEF gel electrophoresis provides a reliable way to quantify the copy number of rDNA repeats in my new strains. The copy number of rDNA increased in my mutant strains to about equal, or even above that of the parent strain. With the rDNA copy number of these new strains restored, I am retesting the previously secondary phenotypes of the orc4MGS strain. Testing is ongoing, but the data suggest that the strains I created now display intermediate phenotypes of growth rate, temperature sensitivity, and drug sensitivity. I conclude from the data that fewer rDNA repeats, as well as the mutant Orc4 protein contribute to the phenotypes observed in the original Meier-Gorlin yeast cells. I am currently determining the efficiency of the new origins in the rDNA, and asking how genome wide origin use has changed. With these experiments I hope to gain insights into some of the cellular mechanisms of Meier-Gorlin Syndrome.